Cell-targeting fusion constructs containing recombinant gelonin

Methods in Enzymology

Volumn 502, Issue , 2012, Pages 167-214

  Lyu, Mi Ae ^a   Cao, Yu ^a   Mohamedali, Khalid A ^a   Rosenblum, Michael G ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Antitumor; Fusion toxins; Gelonin; Immunotoxins; Recombinant proteins; Toxin rGel

Indexed keywords

CASPASE 3; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GELONIN; I KAPPA B KINASE BETA; IMMUNOTOXIN; INDIUM 111; PROTEIN BCL XL; PROTEIN MCL 1; SURVIVIN; TRASTUZUMAB; VASCULOTROPIN; VASCULOTROPIN 121;

ANGIOGENESIS; ARTICLE; BONE CANCER; BONE METASTASIS; BREAST CANCER; CELL LINE; CHORIOALLANTOIS; CYTOTOXICITY; DNA BINDING; DRUG EFFICACY; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE OVEREXPRESSION; HUMAN; IC 50; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; MOLECULARLY TARGETED THERAPY; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN ENGINEERING; RADIOIMMUNOTHERAPY; TUMOR VASCULARIZATION; TUMOR XENOGRAFT; XENOGRAFT;

EID: 84855399797     PISSN: 00766879     EISSN: 15577988     Source Type: Book Series    
DOI: 10.1016/B978-0-12-416039-2.00008-2     Document Type: Chapter

References (86)

1. V. Abramson, and C.L. Arteaga New strategies in HER2-overexpressing breast cancer: Many combinations of targeted drugs available Clin. Cancer Res. 17 5 2011 952 958
2. G.P. Adams, R. Schier, K. Marshall, E.J. Wolf, A.M. McCall, and J.D. Marks Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies Cancer Res. 58 3 1998 485 490 (Pubitemid 28087411)
3. G.P. Adams, C.C. Shaller, L.L. Chappell, C. Wu, E.M. Horak, and H.H. Simmons Delivery of the alpha-emitting radioisotope bismuth-213 to solid tumors via single-chain Fv and diabody molecules Nucl. Med. Biol. 27 4 2000 339 346 (Pubitemid 30628692)
4. S.C. Alley, N.M. Okeley, and P.D. Senter Antibody-drug conjugates: Targeted drug delivery for cancer Curr. Opin. Chem. Biol. 14 4 2010 529 537
5. Z. Cai, H. Zhang, J. Liu, A. Berezov, R. Murali, and Q. Wang Targeting erbB receptors Semin. Cell Dev. Biol. 21 9 2010 961 966
6. Y. Cao, J.D. Marks, J.W. Marks, L.H. Cheung, S. Kim, and M.G. Rosenblum Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: In vitro and in vivo studies Cancer Res. 69 23 2009 8987 8995
7. T.C. Chu, J.W. Marks III, L.A. Lavery, S. Faulkner, M.G. Rosenblum, and A.D. Ellington Aptamer: Toxin conjugates that specifically target prostate tumor cells Cancer Res. 66 12 2006 5989 5992
8. R. Clemente, and J.C. de la Torre Cell-to-cell spread of Borna disease virus proceeds in the absence of the virus primary receptor and furin-mediated processing of the virus surface glycoprotein J. Virol. 81 11 2007 5968 5977 (Pubitemid 46847033)
9. P.M. Coll-Fresno, M. Batoz, S. Tarquin, D. Birnbaum, and F. Coulier Cytotoxic activity of a diptheria toxin/FGF6 mitotoxin on human tumour cell lines Oncogene 14 2 1997 243 247 (Pubitemid 27068310)
10. D. de Jong, and P.O. Balague The molecular background of aggressive B cell lymphomas as a basis for targeted therapy J. Pathol. 223 2011 274 282
11. F. Feuerhake, J.L. Kutok, S. Monti, W. Chen, A.S. LaCasce, and G. Cattoretti NFkappaB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes Blood 106 4 2005 1392 1399 (Pubitemid 41129606)
12. D.M. Fishwild, H.M. Wu, S.F. Carroll, and S.L. Bernhard Characterization of the increased cytotoxicity of gelonin anti-T cell immunoconjugates compared with ricin A chain immunoconjugates Clin. Exp. Immunol. 97 1 1994 10 18 (Pubitemid 24244048)
13. D.J. Flavell Saporin immunotoxins Curr. Top. Microbiol. Immunol. 234 1998 57 61 (Pubitemid 28238004)
14. J.T. Garrett, and C.L. Arteaga Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: Mechanisms and clinical implications Cancer Biol. Ther. 11 9 2011 793 800
15. S.V. Govindan, and D.M. Goldenberg New antibody conjugates in cancer therapy Scientific World Journal 10 2010 2070 2089
16. P. Harris, E. Reed, D.W. King, and N. Suciu-Foca In vitro studies of the effect of MAb NDA 4 linked to toxin on the proliferation of a human EBV-transformed lymphoblastoid B cell line and of gibbon MLA leukemia cell line Cell. Immunol. 134 1 1991 85 95
17. A.A. Hertler, and A.E. Frankel Immunotoxins: A clinical review of their use in the treatment of malignancies J. Clin. Oncol. 7 12 1989 1932 1942 (Pubitemid 20014343)
18. M.V. Hosur, B. Nair, P. Satyamurthy, S. Misquith, A. Surolia, and K.K. Kannan X-ray structure of gelonin at 1.8 A resolution J. Mol. Biol. 250 3 1995 368 380
19. Y. Huang, Y.S. Park, J. Wang, C. Moon, Y.M. Kwon, and H.S. Chung ATTEMPTS system: A macromolecular prodrug strategy for cancer drug delivery Curr. Pharm. Des. 16 21 2010 2369 2376
20. B. Hughes Antibody-drug conjugates for cancer: Poised to deliver? Nat. Rev. Drug Discov. 9 9 2010 665 667
21. M. Hursey, D.L. Newton, H.J. Hansen, D. Ruby, D.M. Goldenberg, and S.M. Rybak Specifically targeting the CD22 receptor of human B-cell lymphomas with RNA damaging agents: A new generation of therapeutics Leuk. Lymphoma 43 5 2002 953 959 (Pubitemid 34460876)
22. S.J. Isakoff, and J. Baselga Trastuzumab-DM1: Building a chemotherapy-free road in the treatment of human epidermal growth factor receptor 2-positive breast cancer J. Clin. Oncol. 29 4 2011 351 354
23. B. Kloo, D. Nagel, M. Pfeifer, M. Grau, M. Duwel, and M. Vincendeau Critical role of PI3K signaling for NF-kappaB-dependent survival in a subset of activated B-cell-like diffuse large B-cell lymphoma cells Proc. Natl. Acad. Sci. USA 108 1 2011 272 277
24. Y.V. Kovtun, and V.S. Goldmacher Cell killing by antibody-drug conjugates Cancer Lett. 255 2 2007 232 240 (Pubitemid 47268641)
25. R.J. Kreitman Toxin-labeled monoclonal antibodies Curr. Pharm. Biotechnol. 2 4 2001 313 325 (Pubitemid 33138540)
26. R.J. Kreitman Recombinant immunotoxins for the treatment of chemoresistant hematologic malignancies Curr. Pharm. Des. 15 23 2009 2652 2664
27. F.C. Kurschus, and D.E. Jenne Delivery and therapeutic potential of human granzyme B Immunol. Rev. 235 1 2010 159 171
28. F.C. Kurschus, M. Kleinschmidt, E. Fellows, K. Dornmair, R. Rudolph, and H. Lilie Killing of target cells by redirected granzyme B in the absence of perforin FEBS Lett. 562 1-3 2004 87 92 (Pubitemid 38388452)
29. Y.M. Kwon, Y. Li, S. Naik, J.F. Liang, Y. Huang, and Y.J. Park The ATTEMPTS delivery systems for macromolecular drugs Expert Opin. Drug Deliv. 5 11 2008 1255 1266
30. G. Lenz, and L.M. Staudt Aggressive lymphomas N. Engl. J. Med. 362 15 2010 1417 1429
31. X. Liu, J. Wu, S. Zhang, C. Li, and Q. Huang Novel strategies to augment genetically delivered. immunotoxin molecular therapy for cancer therapy Cancer Gene Ther. 16 11 2009 861 872
32. M.J. Lord, N.A. Jolliffe, C.J. Marsden, C.S. Pateman, D.C. Smith, and R.A. Spooner Ricin mechanisms of cytotoxicity Toxicol. Rev. 22 1 2003 53 64
33. M.A. Lyu, L.H. Cheung, W.N. Hittelman, J.W. Marks, R.C. Aguiar, and M.G. Rosenblum The rGel/BLyS fusion toxin specifically targets malignant B cells expressing the BLyS receptors BAFF-R, TACI, and BCMA Mol. Cancer Ther. 6 2 2007 460 470 (Pubitemid 46332448)
34. M.A. Lyu, D. Rai, K.S. Ahn, B. Sung, L.H. Cheung, and J.W. Marks The rGel/BLyS fusion toxin inhibits diffuse large B-cell lymphoma growth in vitro and in vivo Neoplasia 12 5 2010 366 375
35. M.A. Lyu, B. Sung, L.H. Cheung, J.W. Marks, B.B. Aggarwal, and C.T. Ricardo The rGel/BLyS fusion toxin inhibits STAT3 signaling via down-regulation of interleukin-6 receptor in diffuse large B-cell lymphoma Biochem. Pharmacol. 80 9 2010 1335 1342
36. A. Mannocci, E. De Feo, C. de Waure, M.L. Specchia, M.R. Gualano, and C. Barone Use of trastuzumab in HER2-positive metastatic breast cancer beyond disease progression: A systematic review of published studies Tumori 96 3 2010 385 391
37. S. Mayes, N. Brown, and T.M. Illidge New antibody drug treatments for lymphoma Expert Opin. Biol. Ther. 11 5 2011 623 640
38. A.M. McCall, G.P. Adams, A.R. Amoroso, U.B. Nielsen, L. Zhang, and E. Horak Isolation and characterization of an anti-CD16 single-chain Fv fragment and construction of an anti-HER2/neu/anti-CD16 bispecific scFv that triggers CD16-dependent tumor cytolysis Mol. Immunol. 36 7 1999 433 445 (Pubitemid 29336224)
39. K.J. McGraw, M.G. Rosenblum, L. Cheung, and D.A. Scheinberg Characterization of murine and humanized anti-CD33, gelonin immunotoxins reactive against myeloid leukemias Cancer Immunol. Immunother. 39 6 1994 367 374 (Pubitemid 24372402)
40. G.D. McIntyre, C.F. Scott Jr., J. Ritz, W.A. Blattler, and J.M. Lambert Preparation and characterization of interleukin-2-gelonin conjugates made using different cross-linking reagents Bioconjug. Chem. 5 1 1994 88 97 (Pubitemid 2043895)
41. K. Mehta, L. Ocanas, F. Malavasi, J.W. Marks, and M.G. Rosenblum Retinoic acid-induced CD38. Antigen as a target for immunotoxin-mediated killing of leukemia cells Mol. Cancer Ther. 3 3 2004 345 352 (Pubitemid 39193710)
42. P.K. Morrow, F. Zambrana, and F.J. Esteva Recent advances in systemic therapy: Advances in systemic therapy for HER2-positive metastatic breast cancer Breast Cancer Res. 11 4 2009 207
43. K. Mujoo, R.A. Reisfeld, L. Cheung, and M.G. Rosenblum A potent and specific immunotoxin for tumor cells expressing disialoganglioside GD2 Cancer Immunol. Immunother. 34 3 1991 198 204
44. C.G. Murphy, and S. Modi HER2 breast cancer therapies: A review Biologics 3 2009 289 301
45. S. Nakamura Overview of 2008 WHO Classification of Malignant Lymphoma Rinsho Byori 58 11 2010 1105 1111
46. A. Negro, and S.D. Skaper Synthesis and cytotoxic profile of a diphtheria toxin-neurotrophin-4 chimera J. Neurochem. 68 2 1997 554 563 (Pubitemid 27044714)
47. D.L. Newton, H.J. Hansen, S.M. Mikulski, D.M. Goldenberg, and S.M. Rybak Potent and specific antitumor effects of an anti-CD22-targeted cytotoxic ribonuclease: Potential for the treatment of non-Hodgkin lymphoma Blood 97 2 2001 528 535 (Pubitemid 32060341)
48. R. Nimmanapalli, M.A. Lyu, M. Du, M.J. Keating, M.G. Rosenblum, and V. Gandhi The growth factor fusion construct containing B-lymphocyte stimulator (BLyS) and the toxin rGel induces apoptosis specifically in BAFF-R-positive CLL cells Blood 109 6 2007 2557 2564 (Pubitemid 46425902)
49. M.J. Ninan, P.D. Wadhwa, and P. Gupta Prognostication of diffuse large B-cell lymphoma in the rituximab era Leuk. Lymphoma 52 3 2011 360 373
50. H. Nogai, B. Dorken, and G. Lenz Pathogenesis of non-Hodgkin's lymphoma J. Clin. Oncol. 29 14 2011 1803 1811
51. P.A. Nolan, D.A. Garrison, and M. Better Cloning and expression of a gene encoding gelonin, a ribosome-inactivating protein from Gelonium multiflorum Gene 134 2 1993 223 227
52. L.C. Pagliaro, B. Liu, R. Munker, M. Andreeff, E.J. Freireich, and D.A. Scheinberg Humanized M195 monoclonal antibody conjugated to recombinant gelonin: An anti-CD33 immunotoxin with antileukemic activity Clin. Cancer Res. 4 8 1998 1971 1976 (Pubitemid 28369183)
53. J.W. Park, D.B. Kirpotin, K. Hong, R. Shalaby, Y. Shao, and U.B. Nielsen Tumor targeting using anti-her2 immunoliposomes J. Control. Release 74 1-3 2001 95 113 (Pubitemid 32727613)
54. J.W. Park, K. Hong, D.B. Kirpotin, G. Colbern, R. Shalaby, and J. Baselga Anti-HER2 immunoliposomes: Eenhanced efficacy attributable to targeted delivery Clin. Cancer Res. 8 4 2002 1172 1181 (Pubitemid 35177372)
55. I. Pastan Immunotoxins containing Pseudomonas exotoxin A: A short history Cancer Immunol. Immunother. 52 5 2003 338 341 (Pubitemid 36578027)
56. A.G. Polson, and M.X. Sliwkowski Toward an effective targeted chemotherapy for multiple myeloma Clin. Cancer Res. 15 12 2009 3906 3907
57. A.G. Polson, J. Calemine-Fenaux, P. Chan, W. Chang, E. Christensen, and S. Clark Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: Target and linker-drug selection Cancer Res. 69 6 2009 2358 2364
58. A.B. Rabson, and D. Weissmann From microarray to bedside: Targeting NF-kappaB for therapy of lymphomas Clin. Cancer Res. 11 1 2005 2 6
59. M.K. Robinson, C. Shaller, K. Garmestani, P.S. Plascjak, K.M. Hodge, and Q.A. Yuan Effective treatment of established human breast tumor xenografts in immunodeficient mice with a single dose of the alpha-emitting radioisotope astatine-211 conjugated to anti-HER2/neu diabodies Clin. Cancer Res. 14 3 2008 875 882 (Pubitemid 351231172)
60. M.G. Rosenblum, and S. Barth Development of novel, highly cytotoxic fusion constructs containing granzyme B: Unique mechanisms and functions Curr. Pharm. Des. 15 23 2009 2676 2692
61. M.G. Rosenblum, J.L. Murray, L. Cheung, R. Rifkin, S. Salmon, and R. Bartholomew A specific and potent immunotoxin composed of antibody ZME-018 and the plant toxin gelonin Mol. Biother. 3 1 1991 6 13
62. M.G. Rosenblum, J.E. Zuckerman, J.W. Marks, J. Rotbein, and W.R. Allen A gelonin-containing immunotoxin directed against human breast carcinoma Mol. Biother. 4 3 1992 122 129
63. M.G. Rosenblum, W.A. Kohr, K.L. Beattie, W.G. Beattie, W. Marks, and P.D. Toman Amino acid sequence analysis, gene construction, cloning, and expression of gelonin, a toxin derived from Gelonium multiflorum J. Interferon Cytokine Res. 15 6 1995 547 555
64. M.G. Rosenblum, L.K. Shawver, J.W. Marks, J. Brink, L. Cheung, and B. Langton-Webster Recombinant immunotoxins directed against the c-erb-2/HER2/neu oncogene product: In vitro cytotoxicity, pharmacokinetics, and in vivo efficacy studies in xenograft models Clin. Cancer Res. 5 4 1999 865 874 (Pubitemid 29180839)
65. K. Sandvig, and B. van Deurs Delivery into cells: Lessons learned from plant and bacterial toxins Gene Ther. 12 11 2005 865 872 (Pubitemid 40852204)
66. P. Satyamurthy, M.V. Hosur, S. Misquith, A. Surolia, and K.K. Kannan Crystallization of a scRIP-gelonin isolated from plant seeds Gelonium multiforum Proteins 19 4 1994 340 342
67. R. Schier, J.D. Marks, E.J. Wolf, G. Apell, C. Wong, and J.E. McCartney In vitro and in vivo characterization of a human anti-c-erbB-2 single-chain Fv isolated from a filamentous phage antibody library Immunotechnology 1 1 1995 73 81
68. J. Schwartz, B. Penke, J. Rivier, and W. Vale A new cytotoxin specific for the target cells of corticotropin-releasing factor Endocrinology 121 4 1987 1454 1460 (Pubitemid 17155895)
69. P.D. Senter Potent antibody drug conjugates for cancer therapy Curr. Opin. Chem. Biol. 13 3 2009 235 244
70. H. Shinohara, S. Morita, M. Kawai, A. Miyamoto, T. Sonoda, and I. Pastan Expression of HER2 in human gastric cancer cells directly correlates with antitumor activity of a recombinant disulfide-stabilized anti-HER2 immunotoxin J. Surg. Res. 102 2 2002 169 177 (Pubitemid 34969464)
71. L. Shivakumar, and S. Ansell Targeting B-lymphocyte stimulator/B-cell activating factor and a proliferation-inducing ligand in hematologic malignancies Clin. Lymphoma Myeloma 7 2 2006 106 108 (Pubitemid 44596592)
72. B. Stahnke, T. Thepen, M. Stocker, R. Rosinke, E. Jost, and R. Fischer Granzyme B-H22 (scFv), a human immunotoxin targeting CD64 in acute myeloid leukemia of monocytic subtypes Mol. Cancer Ther. 7 9 2008 2924 2932
73. L.M. Staudt Oncogenic activation of NF-kappaB Cold Spring Harb. Perspect. Biol. 2 6 2010 a000109
74. F. Stirpe, S. Olsnes, and Pihl A. Gelonin A new inhibitor of protein synthesis, nontoxic to intact cells. Isolation, characterization, and preparation of cytotoxic complexes with concanavalin A J. Biol. Chem. 255 14 1980 6947 6953 (Pubitemid 11234436)
75. A. Stoffel The NF-kappaB signalling pathway: A therapeutic target in lymphoid malignancies? Expert Opin. Ther. Targets 9 5 2005 1045 1061 (Pubitemid 41488839)
76. B.A. Teicher Antibody-drug conjugate targets Curr. Cancer Drug Targets 9 8 2009 982 1004
77. L.M. Veenendaal, H. Jin, S. Ran, L. Cheung, N. Navone, and J.W. Marks In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors Proc. Natl. Acad. Sci. USA 99 12 2002 7866 7871 (Pubitemid 34650971)
78. E.J. Wawrzynczak, and E.J. Derbyshire Immunotoxins to human small-cell lung cancer Cell Biophys. 21 1-3 1992 13 23
79. S. Webb Pharma interest surges in antibody drug conjugates Nat. Biotechnol. 29 4 2011 297 298
80. X. Wen, M.A. Lyu, R. Zhang, W. Lu, Q. Huang, and D. Liang Biodistribution, pharmacokinetics, and nuclear imaging studies of 111In-labeled rGel/BLyS fusion toxin in SCID mice bearing B cell lymphoma Mol. Imaging Biol. 13 4 2011 721 729
81. P. Wolf, and U. Elsasser-Beile Pseudomonas exotoxin A: From virulence factor to anti-cancer agent Int. J. Med. Microbiol. 299 3 2009 161 176
82. R.T. Woodland, M.R. Schmidt, and C.B. Thompson BLyS and B cell homeostasis Semin. Immunol. 18 5 2006 318 326 (Pubitemid 44287557)
83. L. Zhang, J. Zhao, T. Wang, C.J. Yu, L.T. Jia, and Y.Y. Duan HER2-targeting recombinant protein with truncated pseudomonas exotoxin A translocation domain efficiently kills breast cancer cells Cancer Biol. Ther. 7 8 2008 1226 1231
84. T. Zhou, J.D. Mountz, and R.P. Kimberly Immunobiology of tumor necrosis factor receptor superfamily Immunol. Res. 26 1-3 2002 323 336 (Pubitemid 35177509)
85. T. Zhou, J. Zhang, R. Carter, and R. Kimberly BLyS and B cell autoimmunity Curr. Dir. Autoimmun. 6 2003 21 37
86. R. Zielinski, I. Lyakhov, A. Jacobs, O. Chertov, G. Kramer-Marek, and N. Francella Affitoxin - A novel recombinant, HER2-specific, anticancer agent for targeted therapy of HER2-positive tumors J. Immunother. 32 8 2009 817 825